•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Breakfast News: Summit’s FDA Setback Isn’t the End
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
EU panel backs AstraZeneca hypertension drug baxdrostat
AlphaCore Capital LLC Buys 3,357 Shares of AstraZeneca Plc $AZN
AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
Omniose Announces Its Acquisition by AstraZeneca
7,250 Shares of AstraZeneca Plc $AZN Purchased by CenterBook Partners LP
AstraZeneca Plc $AZN Stock: Ethic Inc. Grows Holdings
AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC
1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich
AstraZeneca: 3 Key Takeaways for Long-Term Investors
AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell?
AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC
AstraZeneca (LON:AZN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
Already premium?